Literature DB >> 1487535

A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure.

B J Cox1, N S Endler, P S Lee, R P Swinson.   

Abstract

The most common pharmacological treatments for panic disorder with agoraphobia (PDA) include the use of imipramine and alprazolam while the most common behavior therapy is the use of graded in vivo exposure. Several studies have found these treatments to be superior to placebo in the treatment of PDA, but it has not been clear if there are differences among these three treatments. It has also not been clear for what aspects of PDA each treatment is the most effective. The purpose of this study was to conduct a meta-analysis of the results of relevant treatment outcome studies on a number of dependent variables (e.g., panic attack severity, dysphoria, avoidance behavior). Few studies satisfied the minimum criteria for inclusion and the final data pool consisted of 34 treatment studies. Imipramine was found to be generally ineffective for most variables. Alprazolam was significantly effective for panic and anxiety variables in PDA, while exposure was significantly effective for phobia variables. Exposure had the most consistently strong effect sizes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1487535     DOI: 10.1016/0005-7916(92)90034-g

Source DB:  PubMed          Journal:  J Behav Ther Exp Psychiatry        ISSN: 0005-7916


  6 in total

1.  Interleukin-4 signalling pathway underlies the anxiolytic effect induced by 3-deoxyadenosine.

Authors:  Tangxin Gao; Bai Li; Yangyang Hou; Shaolei Luo; Lei Feng; Jun Nie; Yi Ma; Le Xiao; Xu Chen; Hongkun Bao; Xianmin Lu; Feilong Huang; Gang Wang; Chunjie Xiao; Jing Du
Journal:  Psychopharmacology (Berl)       Date:  2019-04-08       Impact factor: 4.530

Review 2.  Panic disorder.

Authors:  Shailesh Kumar; Darren Malone
Journal:  BMJ Clin Evid       Date:  2008-12-16

3.  Ileal Pouchitis With Endoscopic Pictures.

Authors:  Hassam Ali; Abeera Sarfraz; Hadeera Ali
Journal:  Cureus       Date:  2021-04-30

Review 4.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

5.  Nonpharmacological treatments for anxiety disorders.

Authors:  Jean Cottraux
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

6.  Psychopharmacology of anxiety disorders.

Authors:  Giovanni B Cassano; Nicolò Baldini Rossi; Stefano Pini
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.